Abstract
A new series of 8-halogen-4,4a,5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acids was prepared and tested for aldose reductase (ALR2) inhibitory activities. These compounds showed significant inhibitory activity against bovine lens ALR2, with the best compound 2e showing an IC50 value of 31.4 μM. The presence of the C8-substituents here studied (Cl, Br) on the thienocinnolinone scaffold caused a decrease of the inhibitory potency by a factor of about 4 with respect to the unsubstituted parent compound, while the presence of a C8-methyl group, considered in a previous paper [1] decreased the activity by a factor of about 2. Moreover, the length of the N2 alkanoic chain influences strongly the enzyme inhibitory activity. While most of the carboxylic acids ALR2 inhibitors are acetic acid derivatives, in the case of thienocinnolinone compounds, homologues higher than acetic acids showed to be more active.
Keywords: thieno[h]cinnolinone carboxylic acids, aldose reductase inhibitors, Diabetic complications
Medicinal Chemistry
Title: Thienocinnolinone Alkanoic Acid Derivatives as Aldose Reductase Inhibitors
Volume: 2 Issue: 1
Author(s): G. A. Pinna, D. Rakowitz, L. Costantino, G. E. Grella, G. Boatto, G. Murineddu, B. Asproni and A. Pau
Affiliation:
Keywords: thieno[h]cinnolinone carboxylic acids, aldose reductase inhibitors, Diabetic complications
Abstract: A new series of 8-halogen-4,4a,5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acids was prepared and tested for aldose reductase (ALR2) inhibitory activities. These compounds showed significant inhibitory activity against bovine lens ALR2, with the best compound 2e showing an IC50 value of 31.4 μM. The presence of the C8-substituents here studied (Cl, Br) on the thienocinnolinone scaffold caused a decrease of the inhibitory potency by a factor of about 4 with respect to the unsubstituted parent compound, while the presence of a C8-methyl group, considered in a previous paper [1] decreased the activity by a factor of about 2. Moreover, the length of the N2 alkanoic chain influences strongly the enzyme inhibitory activity. While most of the carboxylic acids ALR2 inhibitors are acetic acid derivatives, in the case of thienocinnolinone compounds, homologues higher than acetic acids showed to be more active.
Export Options
About this article
Cite this article as:
Pinna A. G., Rakowitz D., Costantino L., Grella E. G., Boatto G., Murineddu G., Asproni B. and Pau A., Thienocinnolinone Alkanoic Acid Derivatives as Aldose Reductase Inhibitors, Medicinal Chemistry 2006; 2 (1) . https://dx.doi.org/10.2174/157340606775197769
DOI https://dx.doi.org/10.2174/157340606775197769 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design [General Articles] Aurones: A Subclass of Flavones with Promising Biological Potential
Current Medicinal Chemistry Patent Selections
Recent Patents on Food, Nutrition & Agriculture InhaledInsulin: A Novel and Non-Invasive Way for Insulin Administration?
Current Drug Safety Editorial [Hot Topic: Animal Models for Neurodegenerative Diseases Associated to Accumulation of Misfolded Protein Aggregates (Executive Guest Editor: Claudio Soto)]
Current Pharmaceutical Design Vitamin D Supplementation in Diabetic Foot Ulcers: A Current Perspective
Current Diabetes Reviews Population Studies of Association Between Lithium and Risk of Neurodegenerative Disorders
Current Alzheimer Research MicroRNA in Implant Dentistry: From Basic Science to Clinical Application
MicroRNA On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology “Metabolic Aspects” In Inflammatory Bowel Diseases
Current Drug Delivery Effects of Cichorium Intybus Linn on Blood Glucose, Lipid Constituents and Selected Oxidative Stress Parameters in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry